368 related articles for article (PubMed ID: 1338216)
1. Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta 9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH).
Huestis MA; Henningfield JE; Cone EJ
J Anal Toxicol; 1992; 16(5):283-90. PubMed ID: 1338216
[TBL] [Abstract][Full Text] [Related]
2. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana.
Huestis MA; Henningfield JE; Cone EJ
J Anal Toxicol; 1992; 16(5):276-82. PubMed ID: 1338215
[TBL] [Abstract][Full Text] [Related]
3. Estimating the time of last cannabis use from plasma delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol concentrations.
Huestis MA; Barnes A; Smith ML
Clin Chem; 2005 Dec; 51(12):2289-95. PubMed ID: 16223887
[TBL] [Abstract][Full Text] [Related]
4. Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC.
Karschner EL; Schwope DM; Schwilke EW; Goodwin RS; Kelly DL; Gorelick DA; Huestis MA
Drug Alcohol Depend; 2012 Oct; 125(3):313-9. PubMed ID: 22464363
[TBL] [Abstract][Full Text] [Related]
5. Plasma cannabinoid concentrations during dronabinol pharmacotherapy for cannabis dependence.
Milman G; Bergamaschi MM; Lee D; Mendu DR; Barnes AJ; Vandrey R; Huestis MA
Ther Drug Monit; 2014 Apr; 36(2):218-24. PubMed ID: 24067260
[TBL] [Abstract][Full Text] [Related]
6. Relating blood concentrations of tetrahydrocannabinol and metabolites to pharmacologic effects and time of marijuana usage.
Cone EJ; Huestis MA
Ther Drug Monit; 1993 Dec; 15(6):527-32. PubMed ID: 8122288
[TBL] [Abstract][Full Text] [Related]
7. Oral fluid cannabinoids in chronic, daily Cannabis smokers during sustained, monitored abstinence.
Lee D; Milman G; Barnes AJ; Goodwin RS; Hirvonen J; Huestis MA
Clin Chem; 2011 Aug; 57(8):1127-36. PubMed ID: 21677094
[TBL] [Abstract][Full Text] [Related]
8. Delta(9)-tetrahydrocannabinol, 11-hydroxy-delta(9)-tetrahydrocannabinol and 11-nor-9-carboxy-delta(9)-tetrahydrocannabinol in human plasma after controlled oral administration of cannabinoids.
Goodwin RS; Gustafson RA; Barnes A; Nebro W; Moolchan ET; Huestis MA
Ther Drug Monit; 2006 Aug; 28(4):545-51. PubMed ID: 16885723
[TBL] [Abstract][Full Text] [Related]
9. Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis.
Desrosiers NA; Himes SK; Scheidweiler KB; Concheiro-Guisan M; Gorelick DA; Huestis MA
Clin Chem; 2014 Apr; 60(4):631-43. PubMed ID: 24563491
[TBL] [Abstract][Full Text] [Related]
10. Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations.
Huestis MA; Elsohly M; Nebro W; Barnes A; Gustafson RA; Smith ML
Ther Drug Monit; 2006 Aug; 28(4):540-4. PubMed ID: 16885722
[TBL] [Abstract][Full Text] [Related]
11. In vitro stability of free and glucuronidated cannabinoids in blood and plasma following controlled smoked cannabis.
Scheidweiler KB; Schwope DM; Karschner EL; Desrosiers NA; Gorelick DA; Huestis MA
Clin Chem; 2013 Jul; 59(7):1108-17. PubMed ID: 23519966
[TBL] [Abstract][Full Text] [Related]
12. Oral fluid cannabinoids in chronic frequent cannabis smokers during ad libitum cannabis smoking.
Lee D; Vandrey R; Mendu DR; Murray JA; Barnes AJ; Huestis MA
Drug Test Anal; 2015 Jun; 7(6):494-501. PubMed ID: 25220020
[TBL] [Abstract][Full Text] [Related]
13. Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance.
Karschner EL; Swortwood MJ; Hirvonen J; Goodwin RS; Bosker WM; Ramaekers JG; Huestis MA
Drug Test Anal; 2016 Jul; 8(7):682-9. PubMed ID: 26097154
[TBL] [Abstract][Full Text] [Related]
14. Detectability of various cannabinoids in plasma samples of cannabis users: Indicators of recent cannabis use?
Kraemer M; Madea B; Hess C
Drug Test Anal; 2019 Oct; 11(10):1498-1506. PubMed ID: 31407526
[TBL] [Abstract][Full Text] [Related]
15. Temporal indication of marijuana use can be estimated from plasma and urine concentrations of delta9-tetrahydrocannabinol, 11-hydroxy-delta9-tetrahydrocannabinol, and 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid.
Manno JE; Manno BR; Kemp PM; Alford DD; Abukhalaf IK; McWilliams ME; Hagaman FN; Fitzgerald MJ
J Anal Toxicol; 2001 Oct; 25(7):538-49. PubMed ID: 11599597
[TBL] [Abstract][Full Text] [Related]
16. Quantification of cannabinoids and their free and glucuronide metabolites in whole blood by disposable pipette extraction and liquid chromatography-tandem mass spectrometry.
Scheidweiler KB; Newmeyer MN; Barnes AJ; Huestis MA
J Chromatogr A; 2016 Jul; 1453():34-42. PubMed ID: 27236483
[TBL] [Abstract][Full Text] [Related]
17. Relationship of Delta 9-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis.
Huestis MA; Cone EJ
J Anal Toxicol; 2004 Sep; 28(6):394-9. PubMed ID: 15516285
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of postmortem concentrations of Δ
Hoffman MA; Trochta A; Gary RD; Fitzgerald RL; McIntyre IM
Forensic Sci Int; 2020 Oct; 315():110414. PubMed ID: 32738674
[TBL] [Abstract][Full Text] [Related]
19. Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers.
Karschner EL; Schwilke EW; Lowe RH; Darwin WD; Herning RI; Cadet JL; Huestis MA
J Anal Toxicol; 2009 Oct; 33(8):469-77. PubMed ID: 19874654
[TBL] [Abstract][Full Text] [Related]
20. Urinary cannabinoid disposition in occasional and frequent smokers: is THC-glucuronide in sequential urine samples a marker of recent use in frequent smokers?
Desrosiers NA; Lee D; Concheiro-Guisan M; Scheidweiler KB; Gorelick DA; Huestis MA
Clin Chem; 2014 Feb; 60(2):361-72. PubMed ID: 24185550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
